Kura Sushi to Reproduce Representative Dishes of 70 Countries and Regions Participating in the Osaka-Kansai Expo!
Kura Sushi Inc. (Headquarters: Sakai City, Osaka Prefecture), one of the world’s most popular conveyor-belt sushi chains, announced on December 12 that it will offer 70 new menu items at its restaurant that will open at the “Osaka-Kansai Expo,” which will open on April 13 next year in Yumeshima, Osaka, featuring dishes representing 70 countries and regions scheduled to participate in the Expo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211605079/en/
Antibacterial Sushi Covers with Expo-specific Designs (Photo: Business Wire)
The company is the only major revolving sushi chain in Japan to serve sushi on conveyor belts at all of its restaurants. Under the concept of “Revolving Belts Unite the World,” the company will open a restaurant at the Osaka-Kansai Expo with 338 seats, the most in the company’s history, and a revolving belt about 135 meters long, the longest in the company’s history.
With the intention to bring smiles to the faces of visitors from all over the world and provide them with an enjoyable dining experience, the “Hands・Hands Project,” a project that will offer a special 70 Expo menu representing each country and region scheduled to participate in the Expo, will be launched. The menu has been developed by the company’s product development team. The company’s product development team have been working on these menu items with a focus on reproducing the authentic flavors of the countries and regions. Twenty-four of the items have been recreated after being tasted and advised on by ambassadors and other people from these countries under the collaboration with each embassy.
In addition, the antibacterial sushi cover “Mr. Freshness,” which is being used for this special menu, has been specially designed with the connecting part appearing as red and blue hands shaking, the signature colors of the Expo. By serving the special menu side by side with the company’s popular sushi menu, sushi and dishes from different countries and regions flow hand in hand in front of the customers. Along with enjoying their meal, guests will be able to enjoy the experience as if they were visiting a pavilion that explores the culinary cultures of countries around the world.
To help building momentum for the Expo, special Expo menus will be offered ahead of time at about 550 restaurants nationwide, starting on February 7, 2025 (Friday). Each store will offer one item from a menu of 70 different items, as if each store were a “mini-pavilion” where visitors can enjoy the flavors of the respective country. As every neighborhood store will offer a different menu item from a different country or region, customers will be able to enjoy the menu at their local Kura Sushi restaurants, or they can enjoy all 70 items on the Expo special menu by visiting different Kura Sushi restaurants in Japan.
Kaitenzushi (Revolving Sushi Restaurant) is said to have spread throughout Japan after attracting attention at the Osaka Expo in 1970. Since then, Kaitenzushi has steadily expanded its market size while evolving in various ways over its 50-year history, and is now a leading business category in the evolution of the Japanese food service industry, with sales exceeding 800 billion yen. Going forward, the company will continue to leverage its strength, the revolving belt, to provide customers in Japan and overseas with the memorable enjoyment that only Kura Sushi can offer, thereby expanding the revolving sushi business model, a wonderful business model that originated in Japan, to the entire world.
Mr. Makoto Tanaka, Executive Vice President of Kura Sushi, held a press conference on the day of the event, and mentioned, “These days, the world is filled with a variety of social issues that are difficult to solve. Even under such circumstances, we hope that the conveyor-belt sushi restaurants, which are connected by a “conveyor belt that has no beginning and no end,” will unite people from all over the world who visit the Expo to have an enjoyable dining experience with a smile on their faces. We hope that visitors from all over the world, including Japanese customers, as well as tourists from all over the world, will enjoy the menu which we have created with the combined efforts of our Product Development Division to recreate the authentic flavors of the world.”
As of the end of November, Kura Sushi Inc. operates 547 restaurants in Japan, 70 in the United States, 59 in Taiwan, and 3 in Shanghai.
Check out our other products here. https://www.kurasushi.co.jp/2025expo/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211605079/en/
Contacts
For media inquiries regarding this press release:
Public Relations Department, Kura Sushi, Inc.
E-MAIL: prhq_kurasushi@kura-corpo.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom